While Daniell1 writes that androgen therapy is a proven treatment of anemia in patients with end-stage renal disease (ESRD) through the stimulation of endogenous erythropoietin levels or some other erythropoietic cells, Spivak2 notes in his reply that such an assertion contradicts the known physiology of erythropoiesis. Perhaps I can help resolve some of the conflict. Thirty years ago when we used androgens in the treatment of ESRD, we had just begun to realize that the kidney participated in erythrocyte regulation. At that time, we used a mouse bioassay for detecting the functional presence of erythropoietin, but it could not distinguish between the absence of erythropoietin and the lack of its efficacy due to inhibiters. We then developed an enzyme-linked immunosorbent assay to detect the actual quantities of erythropoietin in patients with ESRD and found that they had higher erythropoietin levels than our control patients and that those levels seemed to be independent of androgen use, transfusion dependency, and hematocrit level (Figure).3 Like Daniell,1 we even postulated at that time that androgens might act by a separate mechanism from erythropoietin. Because the development of biorecombinant erythropoietin was still many years away, we had not yet learned that there were factors such as age, hyperparathyroidism, inflammation, inadequate dialysis, angiotensin antagonists, acidosis, and hyperphosphatemia4 that can produce erythropoietin resistance and distort such relationships as we had chosen to observe. Spivak2 is correct that androgens are neither necessary nor sufficient in the correction of anemia. Since the introduction of biorecombinant erythropoietin, most of the anemia in ESRD is corrected, regardless of endogenous erythropoietin levels. Such a feat was almost never accomplished with androgen therapy before the introduction of biorecombinant erythropoietin, as noted in the Figure. Endogenous erythropoietin levels in ESRD do not seem to predict hematocrit levels or a response to biorecombinant erythropoietin. Recently, we found that increased age alone, unrelated to sex, is associated with resistance to biorecombinant erythropoietin,4 which could explain the association that Daniell1 notes in his figure and has mistakenly attributed to the effect of diminishing endogenous androgens in elderly men. The National Kidney Foundation does not recommend androgens as an adjunctive therapy for erythropoietin resistance because the adverse effects of androgen therapy appear to outweigh its potential benefits. Therefore, investigation of reversal of inhibiters of erythropoietin, such as cytokines like tumor necrosis factor α and defensins like hepcidin, may be a more fruitful pathway in the treatment of erythropoietin resistance.5
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
A, Effect of androgens; B, erythropoietin level vs hematocrit level.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.